European Journal of Cancer
Volume 37, Issue 14 , Pages 1768-1774 , September 2001

Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis

  • N Neymark

      Affiliations

    • EORTC Health Economics Unit, Avenue E. Mounier 83, bte. 11, B 1200 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32-2-774-1655; fax: +32-2-772-6701
    • ,
  • I Adriaenssen

      Affiliations

    • EORTC Health Economics Unit, Avenue E. Mounier 83, bte. 11, B 1200 Brussels, Belgium
    • ,
  • T Gorlia

      Affiliations

    • EORTC Health Economics Unit, Avenue E. Mounier 83, bte. 11, B 1200 Brussels, Belgium
    • ,
  • S Caleo

      Affiliations

    • EORTC Health Economics Unit, Avenue E. Mounier 83, bte. 11, B 1200 Brussels, Belgium
    • ,
  • M Bolla

      Affiliations

    • CHU Grenoble, France
    • ,
  • D Brochon

      Affiliations

    • CHU Grenoble, France

Received 17 January 2001 ,Revised 8 May 2001 ,Accepted 14 May 2001.

References 

  1. Pisters LL. The challenge of locally advanced prostate cancer. Semin. Oncol. 1999;26:202–216
  2. Horwitz EM, Hanlon AL, Hanks GE. Update on the treatment of prostate cancer with external beam irradiation. Prostate. 1998;37:195–206
  3. Tyrrell CJ. Adjuvant and neoadjuvant hormonal therapy for prostate cancer. Eur. Urol. 1999;36:349–358
  4. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl. J. Med. 1997;337:295–300
  5. Bolla M, Collette L, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. Eur J Cancer 1999, 35 (Suppl. 4), s82 (abstr).
  6. Dorosz P. Guide Pratique des Médicaments. Paris: Maloine; 1996;
  7. Nomenclature Générale des Actes Professionels. Union des Caisses Nationales de Sécurités Sociales, Paris, 1994.
  8. Dictionnaire VIDAL. Editions du Vidal, Paris, 1998.
  9. Collett D. Modelling Survival Data in Medical Research. London: Chapmann and Hall; 1994;
  10. Karrison T. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups—interpretation and power considerations. Controlled Clinical Trials. 1997;18:151–167
  11. Lin DY, Feuer U, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53:419–434
  12. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps (a non-parametric approach to confidence interval estimation). Health Econ. 1997;6:327–340
  13. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 1998;7:723–740
  14. Briggs A. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ. 1999;8:257–261
  15. Mark DB, Hlatky MA, Califf RM, et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. NEJM. 1995;332:1418–1424
  16. Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy for high-risk resected cutaneous melanoma. Eur. J. Cancer. 1997;33:1373–1379

PII: S0959-8049(01)00197-6

European Journal of Cancer
Volume 37, Issue 14 , Pages 1768-1774 , September 2001

Article Tools

* Image Usage & Resolution